Конструиране и валидизация на нова скала за вътрешногрупова идентификация

In this study we constructed a scale that measures centrality, social, communal, and interdependent identifi cation, and investigated the distinction between these four different types of identifi cation with social groups. The general aim was to examine the psychometric properties of the newly designed Centrality, Social, Communal, and Interdependent Identifi cation Scale (CSCIIS) and to investigate whether differences in self-construal, relationship orientation, gender, and culture might predict each type of identifi cation. The results provided initial support for the validity and the reliability of the CSCIIS, revealed cross-cultural differences in ingroup identifi cation, and supported predictions regarding the correlations between particular types of relationships orientation and particular types of identifi cation with social groups.Настоящото емпирично изследване се фокусира върху конструирането и валиди- зацията на скала, която измерва централност, социална, общностна, и взаимозависима идентификация и има за цел да направи разграничение между тези четири различни типа идентификация със социални групи. Основната идея е да се проверят психометричните свойства на новосъздадената Скала за централност, социална, общностна и взаимозависи- ма идентификация (СЦСОВИ) и да се установи дали различия в себеконструирането, ори- ентацията към междуличностни взаимоотношения, пола и културата могат да предскажат всеки един тип идентификация. Резултатите предоставят първоначална подкрепа за ва- лидността и надеждността на СЦСОВИ, разкриват междукултурни различия във вътреш- ногруповата идентификация и подкрепят очакванията ни за корелация между определени видове ориентация към междуличностни взаимоотношения и точно определени типове идентификация със социални групи

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation.

The therapeutic landscape of chronic myeloid leukemia (CML) has changed dramatically in the last decade. In particular, the availability of imatinib mesylate, a tyrosine kinase inhibitor targeting BCR-ABL, has led to profound and durable remissions in the majority of patients. However, a couple of issues have emerged and partially obscured this scenario. First, it has become clear that a significant proportion of patients either present with primary resistance to imatinib or develop secondary resistance sooner or later during treatment. Second, although the drug is generally well tolerated, a percentage of patients eventually cease treatment because of toxicity. Bearing this in mind, second-generation tyrosine kinase inhibitors have been introduced, including nilotinib. Phase I and II studies indicate remarkable activity for this compound in CML cases resistant to imatinib, including some of those carrying BCR-ABL1 mutants. More recently, two Phase II studies and a III randomized Phase clinical trial demonstrated the superiority of nilotinib compared with imatinib in terms of complete cytogenetic and major molecular responses, which are two relevant surrogate measures of long-term survival in CML. In this paper, we review the most relevant data on nilotinib as first-line treatment for CML, and discuss the rationale for its routine use, as well as some possible future perspectives for CML patients

More than 650 refugees arrived in this regional town. Locals' welcoming attitudes flipped the stereotype

Over four years, we examined a regional town's attitudes before and after hundreds of refugees settled in the area. Our surveys found residents of Armidale, in northeastern New South Wales, started out reasonably positive about the settlement program, and became even more so.Over time, they had fewer concerns about the impact of refugees on the town, more contact with the refugees, and more positive attitudes towards refugees and the settlement program

Foot Reconstruction

Since the conquest of the upright position, the foot has gained more importance as an organ that supports both the lower limb and the whole body weight and that allows humans to stand up, walk, run, jump, and climb. Human evolution determined progressive changes in both the skeleton architecture and the soft tissue of the foot to cope with the new environmental requirements. From the orangutan to the chimpanzee, from the gorilla to the human, the most important modifications of the skeleton included the progressive reduction of the distal area of the phalanxes with the loss of the grasping function and the enlargement of the proximal bones (astragalus, calcaneum) to obtain a resistant yet flexible structure. See the image below

Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukaemia

The most recent clinical trials on adult acute lymphoid leukaemia (ALL) have shown complete remission and disease-free survival (DFS) rates of 80-85% and 30-40%, respectively (Annino, et al, Durrant, et al, Kantarjian, et al, Larson, et al, Ribera, et al, Rowe). Intensified consolidation, particularly with high-dose methotrexate and high-dose cytarabine, may be one of the reasons for the improved outcome in recent series (Bassan and Hoelzer, Hoelzer and Gokbuget, Kebriaei and Larson). In addition, risk-adapted and subtype-oriented therapy may have contributed to this better outcome. However, the long term outcome of adult patients is still dismal, with approximately one third of the cases only being cured. At present, therapeutic options include conventional chemotherapy (CHT), high dose therapy with autologous and, especially, allogeneic stem cells transplantation (SCT) and, for certain subsets, such as BCR-ABL1+ ALL, specific targeted therapy (Piccaluga, et al). Although SCT has been used in adult ALL for more than 20 years, its role remains controversial as demonstrated by conflicting results in various studies. Previous casecontrolled studies did not show that allogeneic SCT (alloSCT) provided any advantage over CHT (Horowitz, et al, Zhang, et al) while in some studies there was an advantage, but restricted to young adults (Oh, et al). The number of controlled published or ongoing trials is remarkably small and some of them did not include both standard-risk and high-risk patients. Thus, it is difficult to draw definitive conclusions from their results. In fact, while some authors did not report any differences between alloSCT and chemotherapy or autologous SCT (ASCT)(Gupta, et al, Labar, et al), others only found differences favouring allogeneic SCT in standard risk (Goldstone, et al) or high-risk ALL patients (Sebban, et al, Thiebaut, et al, Thomas, et al). In this chapter, the Authors reviewed data concerning alloSCT in adult ALL and discuss current controversial and possible perspectives

Identity and Deprovincialization: Identity Complexity and Inclusiveness Encourage EU-Wide Behavioural Intentions via Reduced Intergroup Concerns and Increased Optimism

This research aimed at identifying social psychological processes contributing to deprovincialising behaviours (Pettigrew, 1997), which support social integration in Europe. We tested whether EU residents’ sense of identity, defined as complex (Linville, 1982; Brewer & Pierce, 2005) and inclusive (Dovidio, Gaertner, & Saguy, 2009), orient them toward EU-wide behaviours by mitigating intergroup concerns toward crime, immigration, and terrorism – and by improving optimism about their future within the EU. European adults ('N' = 28,004; females 54.3%; age 'M' = 50.05, 'SD' = 18.34) residing in one of the 28 EU member states completed the 2014 Eurobarometer survey (Standard EB 81, 2014) and contributed to our key analyses. Mediation analyses confirmed that reduced intergroup concerns and general optimism acted as pathways to pro-Europe integration orientations associated with complex and inclusive identities. This work highlights the promising value of deprovincialization as a concept that imbues both a behavioural and a time dimension

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

BACKGROUND: The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1 molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective. Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options in these cases. CASE PRESENTATION: We here report the case of a young Ph+ ALL patient who relapsed on front-line dasatinib therapy because of two independent T315I-positive subclones, resulting from different nucleotide substitutions -one of whom never reported previously- and where additional mutant clones outgrew and persisted despite ponatinib, transplant, blinatumomab and conventional chemotherapy. Deep Sequencing (DS) was used to dissect the complexity of BCR-ABL1 kinase domain (KD) mutation status and follow the kinetics of different mutant clones across the sequential therapeutic approaches. CONCLUSIONS: This case presents several peculiar and remarkable aspects: i) distinct clones may acquire the same amino acid substitution via different nucleotide changes; ii) the T315I mutation may arise also from an 'act' to 'atc' codon change; iii) the strategy of temporarily replacing TKI therapy with chemo or immunotherapy, in order to remove the selective pressure and deselect aggressive mutant clones, cannot always be expected to be effective; iv) BCR-ABL1-mutated sub-clones may persist at very low levels (undetectable even by Deep Sequencing) for long time and then outcompete BCR-ABL1-unmutated ones becoming dominant even in the absence of any TKI selective pressure

3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells

Immunotherapy efficacy relies on the crosstalk within the tumor microenvironment between cancer and dendritic cells (DCs) resulting in the induction of a potent and effective antitumor response. DCs have the specific role of recognizing cancer cells, taking up tumor antigens (Ags) and then migrating to lymph nodes for Ag (cross)-presentation to naïve T cells. Interferon-α-conditioned DCs (IFN-DCs) exhibit marked phagocytic activity and the special ability of inducing Ag-specific T-cell response. Here, we have developed a novel microfluidic platform recreating tightly interconnected cancer and immune systems with specific 3D environmental properties, for tracking human DC behaviour toward tumor cells. By combining our microfluidic platform with advanced microscopy and a revised cell tracking analysis algorithm, it was possible to evaluate the guided efficient motion of IFN-DCs toward drug-treated cancer cells and the succeeding phagocytosis events. Overall, this platform allowed the dissection of IFN-DC-cancer cell interactions within 3D tumor spaces, with the discovery of major underlying factors such as CXCR4 involvement and underscored its potential as an innovative tool to assess the efficacy of immunotherapeutic approaches